Interestingly, the analysis of MYBBP1A low tumor samples by different subtypes of RCC points to MYBBP1A loss is more frequent in chRCCs, which could be a suitable subgroup to target oxidative pathways as an alternative therapeutic approach. This evidence concerns the gene MYBBP1A and neoplasm.